1794811-58-7
1794811-58-7
Chemical Structure
Niflumic Acid-d5
- CAS No.: 1794811-58-7
- Formula:C13H4D5F3N2O2
- Molecular Weight:287.25
IUPAC Name: 2-((3-(trifluoromethyl)phenyl-5,6-d2)amino)nicotinic-4,5,6-d3 acid
InChIKey: JZFPYUNJRRFVQU-UPLZBMDUSA-N
SMILES: N(C1=C(C(O)=O)C(=C(C(=N1)[2H])[2H])[2H])C2=CC(C(F)(F)F)=CC(=C2[2H])[2H]
Biological Activity: Niflumic Acid-d5 is the deuterium labeled Niflumic acid. Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Niflumic Acid-d5 | Niflumic Acid-d5 is the deuterium labeled Niflumic acid. Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Niflumic acid (Standard) | 99.93% | Niflumic acid (Standard) is the analytical standard of Niflumic acid. This product is intended for research and analytical applications. Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Niflumic acid-13C6 | 99.8% | Niflumic acid-13C6 is the 13C6 labeled Niflumic acid. Niflumic acid, a Ca2+-activated Cl- channel blocker, is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Niflumic acid | 99.61% | Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Criddle, D.N., et al., Inhibitory action of niflumic acid on noradrenaline- and 5-hydroxytryptamine-induced pressor responses in the isolated mesenteric vascular bed of the rat. Br J Pharmacol, 1997. 120(5): p. 813-8. [Content Brief]
